Pharmaceutical and biotech development of cannabinoid-based drugs has recently become a highly active and fertile ground for the generation of a new class of regulated therapeutics. The combination of advancements in our biological understanding of the endocannabinoid system with the production of natural and synthetic cannabinoid products is now being shown to have myriad therapeutic value for unmet medical conditions. The inaugural International Cannabinoid-Based Drug Discovery and Development (iCBD3) Congress will explore an array of drug targets, therapies, manufacturing processes, regulatory frameworks, clinical studies and market opportunities for cannabinoid-based pharmaceuticals.